Vectura Prevails In US Litigation Over GSK’s Ellipta

 
• By Dave Wallace

Vectura has won an award of almost $90m after convincing a Delaware jury that GSK’s Ellipta respiratory range infringed one of its US patents. The firm currently has a development deal with Hikma for generic versions.

Courtroom
A jury has decided in favor of Vectura in a US patent battle with GSK • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin